Call alert · Horizon Europe · EU Missions
Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
HORIZON-MISS-2027-02-CANCER-03
HORIZON-MISS-2027-02-CANCER-03 — “Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes” — is a forthcoming Horizon Europe call. It opens on 10 February 2027 and the deadline is 16 September 2027.
Key facts
- Call identifier
- HORIZON-MISS-2027-02-CANCER-03
- Programme
- Horizon Europe · EU Missions
- Status
- Forthcoming
- Opens
- 10 February 2027
- Deadline
- 16 September 2027 (316 days left)
- Budget
- ≈ €7M–€9M / project
- Keywords
- Clinical Research, Common Cancers, High Income Countries, Oncology Nurses, Precision Oncology
Official call page
HORIZON-MISS-2027-02-CANCER-03 on the EU Funding & Tenders Portal — eligibility conditions, topic description, expected outcomes and submission system.
Frequently asked questions
When is the deadline for HORIZON-MISS-2027-02-CANCER-03?
The deadline is 16 September 2027. Funding & Tenders Portal deadlines usually close at 17:00 Brussels time; always confirm the exact time on the official call page.
What is the budget of HORIZON-MISS-2027-02-CANCER-03?
The published budget is ≈ €7M–€9M / project.
Where do I apply for HORIZON-MISS-2027-02-CANCER-03?
Proposals are submitted electronically through the EU Funding & Tenders Portal, using the link to the official call page on this page.